rs1799999 — PPP1R3A Asp905Tyr

Missense variant in the skeletal muscle glycogen-targeting subunit of protein phosphatase 1 (PP1); reduces effective PP1 activity at the glycogen particle, impairing insulin-stimulated glycogen synthesis and increasing type 2 diabetes risk

See your personal result for PPP1R3A

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PPP1R3A Asp905Tyr — When the Muscle's Glycogen Switch Misfires

Skeletal muscle is the largest glucose sink in the human body, and most of that glucose enters storage as glycogen11 glycogen
A branched polymer of glucose units stored primarily in liver and skeletal muscle; the body's primary short-term energy reserve. The enzyme that builds glycogen — glycogen synthase — is held in check by phosphorylation and activated when protein phosphatase 1 (PP1)22 protein phosphatase 1 (PP1)
A ubiquitous serine/threonine phosphatase that dephosphorylates and thus activates glycogen synthase in response to insulin removes those inhibitory phosphate groups. PP1 doesn't float freely through the muscle cell; it is tethered to the glycogen particle itself by a targeting subunit called GM (encoded by PPP1R3A). Without GM, PP1 can't find glycogen synthase efficiently enough to respond to insulin. The rs1799999 variant (Asp905Tyr, C>A on the plus strand) changes an aspartate to a tyrosine at position 905 of GM, subtly altering the protein's function at this critical glycogen–enzyme interface.

The Mechanism

PPP1R3A encodes the muscle-specific glycogen-targeting subunit GM of PP1. GM coordinates three processes at the glycogen granule: it activates glycogen synthase (building glycogen), inactivates glycogen phosphorylase (preventing glycogen breakdown), and is itself regulated by insulin signaling. When insulin rises after a meal, the GM–PP1 complex is the molecular switch that tells muscle to absorb glucose and convert it to glycogen.

The Asp905Tyr substitution falls near the GM C-terminus, a region involved in glycogen-binding and PP1 catalytic subunit docking33 glycogen-binding and PP1 catalytic subunit docking
The C-terminal domain of glycogen-targeting subunits contains glycogen-binding sites and residues that orient the PP1 catalytic unit toward its substrates. A 2003 knockout study in mice showed that complete loss of PPP1R3A reduces skeletal muscle glycogen 10-fold, causes weight gain, and eventually produces insulin resistance44 reduces skeletal muscle glycogen 10-fold, causes weight gain, and eventually produces insulin resistance
Delibegovic et al. Disruption of PPP1R3A leads to increased weight gain, fat deposition, and insulin resistance. Diabetes, 2003. This establishes that GM is not optional for normal muscle glucose handling.

Whether the Asp905Tyr point mutation exerts a similar (if milder) effect is less settled: an in vitro study55 in vitro study
Rasmussen et al. Diabetologia, 2000 — L6 rat myotubes expressing Asp905 vs Tyr905 via adenovirus found no significant difference in glycogen synthesis between the two variants, suggesting that the substitution alone may not be sufficient to impair PP1–GM function in isolated muscle cells. However, in living organisms, the interaction between the Tyr905 allele and other metabolic stressors — particularly obesity — appears to matter.

The Evidence

The evidence for rs1799999 is mixed but points toward a context-dependent risk factor. In a case-control study of 600 Mayan Mexicans, Sánchez-Pozos et al. 201866 Sánchez-Pozos et al. 2018
Whole-exome sequencing in Maya indigenous families: variant in PPP1R3A is associated with T2D. Mol Genet Genomics, 2018 found an OR of 1.625 (p=0.014) for T2D, with carriers showing elevated HOMA-IR values — a direct measure of insulin resistance. The indigenous Mexican population was chosen in part because of high background T2D prevalence, which may amplify detectable genetic effects.

A Swedish male cohort (n=696) found the Tyr905 allele frequency to be approximately 0.11 — similar to gnomAD European estimates — but neither Asp905Tyr nor the linked 3'UTR polymorphism independently predicted diabetes progression77 neither Asp905Tyr nor the linked 3'UTR polymorphism independently predicted diabetes progression
Hansen et al. Polymorphism in PPP1R3 and insulin sensitivity. Diabetes, 2000 over 20-year follow-up. A brief letter in 2007 (Mammarella et al.88 Mammarella et al.
Obesity modifies the effects of Asp905Tyr on T2D risk. Diabetes Obes Metab, 2007) reported that obesity modifies the effect of the variant on T2D risk and insulin sensitivity — suggesting that the Tyr905 allele confers meaningful risk primarily when metabolic stress is already elevated.

Taken together, the Asp905Tyr variant appears to reduce the margin for normal muscle glycogen metabolism rather than abolish it. Carriers are more vulnerable to insulin resistance when other metabolic challenges (obesity, sedentary lifestyle, high glycemic load) are also present.

Practical Actions

For carriers of the Tyr905 (A) allele, the key intervention is protecting the muscle glycogen pathway from additional stress. This means keeping postprandial glucose load moderate — so the PP1–GM system is not overwhelmed by high glucose flux — and maintaining muscle mass and insulin sensitivity through resistance training, which upregulates the entire glucose-uptake machinery and partially compensates for reduced PP1 efficiency.

Monitoring fasting insulin and HOMA-IR is more informative here than fasting glucose alone, because insulin resistance elevates insulin before glucose levels rise. Detecting rising HOMA-IR early allows dietary correction before clinical hyperglycemia appears.

Interactions

PPP1R3A works downstream of the insulin receptor signaling cascade and within the same glycogen-synthesis pathway as GYS1 (glycogen synthase, muscle isoform). A compound effect between rs1799999 and GYS1 variants — particularly rs2287944 and rs1566900 — is biologically plausible: impaired PP1 activity (PPP1R3A) combined with reduced glycogen synthase capacity (GYS1) would doubly impair postprandial glucose storage. No published compound study has yet quantified this combination in humans, but pathway-aware monitoring (HOMA-IR, postprandial glucose) would detect it.

The variant also shows linkage disequilibrium with a 3'UTR ARE polymorphism in PPP1R3A that reduces mRNA stability — carriers of rs1799999 may also carry the 3'UTR variant, compounding reduced protein function with reduced protein expression.

Nutrient Interactions

glucose altered_metabolism
glycogen impaired_conversion

Genotype Interpretations

What each possible genotype means for this variant.

CC Normal GM Function Normal

Two copies of the common Asp905 allele — normal PP1-GM glycogen targeting activity

You carry two copies of the C allele at rs1799999, encoding the common Asp905 form of the GM subunit. This genotype is associated with normal protein phosphatase 1 activity at the muscle glycogen particle and standard insulin-stimulated glycogen synthesis. About 74% of the global population (and ~83% of Europeans) share this genotype.

AC Heterozygous Tyr905 Intermediate

One copy of Tyr905 — moderately reduced PP1-GM efficiency, especially when combined with metabolic stress

The Tyr905 allele has a frequency of ~0.10 in Europeans and ~0.69 in East Asians (gnomAD v4). An OR of 1.625 for T2D was observed in a Mayan Mexican case-control study (PMID 29948331), though the Asp905Tyr variant did not independently predict diabetes in a 20-year Swedish cohort. A 2007 report noted that obesity significantly modifies the variant's effect on both T2D risk and insulin sensitivity.

The in vitro finding that Asp905 and Tyr905 produce equivalent glycogen synthesis in isolated myotubes (PMID 10907117) suggests the variant's impact is context-dependent rather than constitutive — perhaps requiring additional metabolic challenges (high glucose flux, adipokine signaling, or inflammation) to manifest.

AA Homozygous Tyr905 High Risk

Two copies of Tyr905 — highest genetic loading for impaired PP1-GM glycogen targeting and insulin resistance risk

The homozygous Tyr905 state represents the maximum genetic loading at this locus. In skeletal muscle, PPP1R3A coordinates insulin-stimulated glycogen synthesis by anchoring PP1 at the glycogen particle. Complete disruption of this subunit in mice produces a 10-fold reduction in muscle glycogen (PMID 12606498) with eventual insulin resistance and 20% excess weight gain. The Asp905Tyr substitution is a partial loss-of-function relative to the knockout, but AA homozygotes have no wild-type GM copies to compensate.

The Tyr905 allele is extremely common in East Asian populations (~69% allele frequency), which may reflect founder effects or neutral drift at this locus in that population. High T2D rates in East Asian populations are multifactorial and should not be attributed primarily to this variant, but it may contribute to an elevated background susceptibility.

Obesity amplifies the variant's effect substantially — maintaining a healthy body composition is the single most powerful modifier of this genetic risk.